Treprostinil palmitil inhalation powder leverages endogenous lung enzymes to provide sustained treprostinil

Tam L. Nguyen(Insmed (United Kingdom)), Christina C. Chang(Insmed (United Kingdom)), David Cipolla(Insmed (United Kingdom)), Vladimir Malinin(Insmed (United Kingdom)), Walter R. Perkins(Insmed (United States)), Veronica Viramontes(Insmed (United Kingdom)), Junguo Zhou(Insmed (United Kingdom)), Michel R. Corboz(Insmed (United Kingdom))
Expert Opinion on Drug Delivery
August 2, 2024
Cited by 3

Abstract

BACKGROUND: To determine key enzymes enabling treprostinil palmitil (TP) conversion to treprostinil and the main converting sites in the respiratory system. RESEARCH DESIGN AND METHODS: We performed in vitro activity assays to identify lung enzymes hydrolyzing TP, and cell-based assays and immunostainings to establish the likely locations within the lung. RESULTS: Lipoprotein lipase (LPL) had greater activity than the other tested lung enzymes. Excess LPL activity was present both in vitro and at the target TP dose in vivo. CONCLUSIONS: LPL is likely the key enzyme enabling TP conversion. The rate-limiting step is likely the accessibility of TP and not the enzyme activity.


Related Papers

No related papers found

Powered by citation graph analysis